Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 12/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24223658 | 1.00 | FFAR4 (0.44) | FFAR4FFAR1PIM1PDE2ACES2 | |
| SCHEMBL24223271 | 0.81 | FFAR4 (0.41) | FFAR4FFAR1PIM1PDE2A | |
| SCHEMBL24180147 | 0.79 | PDE2A (0.44) | FFAR4FFAR1PIM1PDE2ACYP2C9 | |
| SCHEMBL20472383 | 0.77 | PDE2A (0.51) | PDE2A | |
| SCHEMBL6400522 | 0.76 | PDE2A (0.47) | PDE2ACES2CES1 | |
| SCHEMBL6400520 | 0.76 | PDE2A (0.47) | PDE2ACES2CES1 | |
| SCHEMBL6400526 | 0.76 | PDE2A (0.47) | PDE2ACES2CES1 | |
| SCHEMBL31135330 | 0.75 | PDE2A (0.40) | FFAR4FFAR1PIM1PDE2AGPR3 | |
| SCHEMBL12263421 | 0.75 | PDE2A (0.51) | FFAR4FFAR1PDE2ACES1GPR3 | |
| SCHEMBL14763132 | 0.75 | LMNA (0.50) | PDE2AEPHX2AURKATPX2GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621916-B1 | BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2016-02-10 | — | — | EP | disclosed |
| US-9029357-B2 | Benzazole derivatives as histamine H4 receptor ligands | BIOPROJET (FR) | 2015-05-12 | — | — | US | disclosed |
| US-20150004181-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | BIOPROJET SOC CIV (FR) | 2015-01-01 | — | — | US | disclosed |
| US-8802664-B2 | Benzazole derivatives as histamine H4 receptor ligands | BIOPROJECT (FR) | 2014-08-12 | — | — | US | disclosed |
| US-20130231329-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | BIOPROJET (FR) | 2013-09-05 | — | — | US | disclosed |
| EP-2621916-A1 | BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS | BIOPROJET (FR) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012041860-A1 | BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS | BIOPROJET (FR) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150004181-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | HRH4, HRH3, HRH2 | FFAR4 112/4885FFAR1 626/4885PIM1 2855/4885 |
| US-20130231329-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | HRH4, HRH3, HRH2 | FFAR4 71/4885FFAR1 230/4885PIM1 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.